Glaukos Corporation (GKOS)

107,29 -0,44 (-0,40%) In data: 01:12PM EDT. Mercato aperto.

Glaukos Corporation

One Glaukos Way
Aliso Viejo, CA 92656
United States
949 367 9600
https://www.glaukos.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 907

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas William Burns	Chairman & CEO	774,9k	24,98M	1961
Mr. Joseph E. Gilliam	President & COO	1,18M	4,01M	1976
Mr. Alex R. Thurman	Senior VP & CFO	621,24k	N/D	1970
Dr. Tomas Navratil Ph.D.	Chief Development Officer	866,18k	N/D	1977
Dr. Mory Gharib Ph.D.	Co-Founder	N/D	N/D	N/D
Mr. Christopher William Lewis	Vice President of Investor Relations & Corporate Affairs	N/D	N/D	N/D
Ms. Diana A. Scherer	VP of Compliance & Deputy General Counsel	N/D	N/D	N/D
Ms. Michele M. Allegretto	Senior Vice President of Human Resources	N/D	N/D	N/D
Mr. Chris M. Calcaterra	Executive Vice President of Global Commercial Operations	198,66k	N/D	1960
Ms. Jane E. Rady	Senior Vice President of Corporate Strategy & Business Development	N/D	N/D	1948

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Governance aziendale

L'ISS Governance QualityScore di Glaukos Corporation al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.